Beyond MEN1, When to Think About MEN4? Retrospective Study on 5600 Patients in the French Population and Literature Review
The Journal of Clinical Endocrinology & Metabolism · 17.06.2024 · 109 (7) · e1482-e1493
DOI: 10.1210/clinem/dgae055 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 30.01.2024. Verfasst von Benjamin Chevalier und 36 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Diabetology and Metabolism, Lille University Hospital, 59000 Lille, France. Hauptthemen laut MEDLINE: Multiple Endocrine Neoplasia Type 1. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 67 Literaturangaben.
Abstract (Originalsprache)
Context
Germline CDKN1B variants predispose patients to multiple endocrine neoplasia type 4 (MEN4), a rare MEN1-like syndrome, with <100 reported cases since its discovery in 2006. Although CDKN1B mutations are frequently suggested to explain cases of genetically negative MEN1, the prevalence and phenotype of MEN4 patients is poorly known, and genetic counseling is unclear.
Objective
To evaluate the prevalence of MEN4 in MEN1-suspected patients and characterize the phenotype of MEN4 patients.
Design
Retrospective observational nationwide study. Narrative review of literature and variant class reassessment. Patients We included all adult patients with class 3/4/5 CDKN1B variants identified by the laboratories from the French Oncogenetic Network on Neuroendocrine Tumors network between 2015 and 2022 through germline genetic testing for MEN1 suspicion. After class reassessment, we compared the phenotype of symptomatic patients with class 4/5 CDKN1B variants (ie, with genetically confirmed MEN4 diagnosis) in our series and in literature with 66 matched MEN1 patients from the UMD-MEN1 database.
Results
From 5600 MEN1-suspected patients analyzed, 4 with class 4/5 CDKN1B variant were found (0.07%). They presented with multiple duodenal NET, primary hyperparathyroidism (PHPT) and adrenal nodule, isolated PHPT, PHPT, and pancreatic neuroendocrine tumor. We listed 29 patients with CDKN1B class 4/5 variants from the literature. Compared with matched MEN1 patients, MEN4 patients presented lower NET incidence and older age at PHPT diagnosis.
Conclusion
The prevalence of MEN4 is low. PHPT and pituitary adenoma represent the main associated lesions, NETs are rare. Our results suggest a milder and later phenotype than in MEN1. Our observations will help to improve genetic counseling and management of MEN4 families.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Diabetology and Metabolism, Lille University Hospital, 59000 Lille, France.
- University of Lille, 59000 Lille, France.
- Department of Nuclear Medicine, Lille University Hospital, 59000 Lille, France.
- University of Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277-CANTHER-Cancer-Heterogeneity Plasticity and Resistance to Therapies, 59000 Lille, France.
- CHU Lille, Service de Biochimie et Biologie moléculaire « Hormonologie, Métabolisme-Nutrition, Oncologie, 59000 Lille, France.
- Laboratory of Molecular Biology GEnOPé, Biogénopôle, Aix Marseille Univ, APHM, INSERM, UMR1251 MMG, Hôpital de la Timone, 13005 Marseille, France.
ORCID-Profile: Benjamin Chevalier, Lucie Coppin, Pauline Romanet, Thomas Cuny, Jean-Christophe Maïza, Juliette Abeillon, Thomas Walter, Maëlle Le Bras, Sarra Smati, Solange Grunenwald, Céline Mouly, Eugénie Koumakis, Arnaud Jannin, Stéphanie Espiard, Éric Baudin, Mathias Cavaille, Igor Tauveron, Marie-Pierre Teissier, Françoise Borson-Chazot, Delphine Mirebeau-Prunier, Frédérique Savagner, Éric Pasmant, Sophie Giraud, Marie-Christine Vantyghem, Pierre Goudet, Anne Barlier, Marie Françoise Odou
Zitieren
APA
Chevalier, B., Coppin, L., Romanet, P., Cuny, T., Maïza, J. C., Abeillon, J., Forestier, J., Walter, T., Gilly, O., Le Bras, M., Smati, S., Nunes, M. L., Geslot, A., Grunenwald, S., Mouly, C., Arnault, G., Wagner, K., Koumakis, E., Cortet-Rudelli, C., …, & Odou, M. F. (2024). Beyond MEN1, When to Think About MEN4? Retrospective Study on 5600 Patients in the French Population and Literature Review. The Journal of Clinical Endocrinology & Metabolism, 109(7), e1482-e1493. https://doi.org/10.1210/clinem/dgae055
Vancouver
Chevalier B, Coppin L, Romanet P, Cuny T, Maïza JC, Abeillon J, et al. Beyond MEN1, When to Think About MEN4? Retrospective Study on 5600 Patients in the French Population and Literature Review. The Journal of Clinical Endocrinology & Metabolism. 2024;109(7):e1482-e1493. doi:10.1210/clinem/dgae055
BibTeX
@article{Chevalier2024,
author = {Chevalier, Benjamin and Coppin, Lucie and Romanet, Pauline and Cuny, Thomas and Maïza, Jean-Christophe and Abeillon, Juliette and Forestier, Julien and Walter, Thomas and Gilly, Olivier and Le Bras, Maëlle and Smati, Sarra and Nunes, Marie Laure and Geslot, Aurore and Grunenwald, Solange and Mouly, Céline and Arnault, Gwenaelle and Wagner, Kathy and Koumakis, Eugénie and Cortet-Rudelli, Christine and Merlen, Émilie and Jannin, Arnaud and Espiard, Stéphanie and Morange, Isabelle and Baudin, Éric and Cavaille, Mathias and Tauveron, Igor and Teissier, Marie-Pierre and Borson-Chazot, Françoise and Mirebeau-Prunier, Delphine and Savagner, Frédérique and Pasmant, Éric and Giraud, Sophie and Vantyghem, Marie-Christine and Goudet, Pierre and Barlier, Anne and Cardot-Bauters, Catherine and Odou, Marie Françoise},
title = {Beyond MEN1, When to Think About MEN4? Retrospective Study on 5600 Patients in the French Population and Literature Review},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
volume = {109},
number = {7},
pages = {e1482--e1493},
doi = {10.1210/clinem/dgae055}
}
EUVIMED